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Abstract: There are physiological consequences of overeating that can lead to increased
morbidity and mortality. Purpose of this review article is to acquaint the reader with the
current state of the art in the non-cardiac gated, non-contrast chest Computed
Tomographic (NCCT) imaging biomarkers of the metabolic syndrome (MetS) and their
prognostic significance found in the lower neck and chest.  NCCT Imaging biomarkers,
associated with MetS in the chest include premature coronary artery calcification,
acceleration of large vessel arterial and valvular calcifications associated with
atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension
associated with sleep apnea. These easily identified imaging biomarkers have
prognostic implications for Major Adverse Cardiac Events (MACE). These NCCT chest-
imaging biomarkers are likely targets for artificial intelligence algorithms to harvest for
longitudinal assessment of their individual and multifactorial contributions to chronic
disease, MACE and mortality. Early recognition and treatment of these common
disorders may help improve patient outcomes and quality of life while decreasing
medical costs.
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Title: NON-CONTRAST CHEST COMPUTED TOMOGRAPHY OF OBESITY AND THE METABOLIC SYNDROME 
(METS): PART I CARDIOVASCULAR FINDINGS 
 
Dear Dr. Schoepf, 
 
Thank you for the opportunity to participate in the JTI Special Issue for January 2019. 
We have made the suggested changes in the manuscript according to your and the reviewer comments. 
Each comment is listed in order below. Our responses and changes in the manuscript put into  
are highlighted in yellow.   We have changed the title slightly so that Part I and Part 2 have the same 
wording. Specifically the two words “Obesity and” have been added. We also added a supplemental 
figure from Raul Estepar’s group on segmenting the left ventricle on non contrast non gated chest CT 
exams. 
 




1. Please name NCCT as Non contrast chest computed tomography in the abbreviation page. 
Done 
NCCT                      Non contrast Computed Tomography 
 
 
2. In Heart and Valves Section - "...While all cardiac structures are affected by cardiac motion, there is 
increasing evidence that, with newer hardware low-dose NG-NCCT cardiac motion is less of a problem 
for calcification and myocardial scar assessment/quantification..) Please use the relevant references to 
support the mentioned evidence. Equally importantly please ensure that motion artefact especially in 
the assessment of small anatomical structures as coronary arteries, coronary artery calcifications can be 
influenced by heart rate dependent motion artefact and also the chosen CT protocol. 
Good point here. We have added the following. 
Cover Letter
While all cardiac structures are affected by cardiac motion, there is increasing evidence that, with newer hardware, 
and faster gantry rotation times, low-dose NG-NCCT cardiac motion is less of a problem for calcification and 
myocardial scar assessment/quantification (Figures 1-4).(12-15) 
 
 
3. In Coronary Artery Calcification section - It is proper to use the reference of Wu et al about the 
correlation between gated and non gated CT protocol based coronary calcium assessment. The authors 
mentioned an explanation that the quoted good correlation is due to thinner slice reconstruction which 
is misleading. The referenced article from 2008 used 16 slice MDCT with a mean heart rate of around 
61beats/min. Thus it is important to emphasize in the presented review the importance of potential 
heart rate dependent motion artefact that can limit potentially significantly the accurate quantification 
of calcium score using non gated CT protocols. 
We have added the following: 
 
In a study by Wu et al (28) on 483 patients showed excellent correlation of Agatston CAC scores between a 
dedicated cardiac gated non-contrast CT for calcium scoring (16 slice multidetector, 3.0 mm slice thickness) and a 
low dose NG-NCCT ( 16 slice multidector,  0.75mm slice thickness )performed for lung cancer screening (Figure 1). 
In their cohort of NG-NCCT patients the average heart was 61 beats per minute. They did not assess the 
importance of potential heart rate dependent motion artifact that may limit the accurate quantification of calcium 




4. It would be beneficial to have a section of Radiation since the presented evidence may support 
potential CT screening for patients with Metabolic Syndrome. 
We have added the following: 
Radiation dose and safety using NG-NCCT for the diagnosis of MetS 
 We are not proposing to use NCCT for the diagnosis of MetS or obesity. From studies performed for other 
indications, the imaging physician can also make inferences about the metabolic milieu of that subject based on the 
multiple imaging findings discussed in this review. For the most, part low dose chest CT protocols are very low 
contributors to the medical radiation any patient receives over the course of their lifetime.(78)  Each scan delivers 
between 0.5 and 5 mSv depending on the patient size, use of dose lowering reconstruction methods and automatic 
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There are physiological consequences of overeating that can lead to increased morbidity and mortality. Purpose of 
this review article is to acquaint the reader with the current state of the art in the non-cardiac gated, non-contrast 
chest Computed Tomographic (NCCT) imaging biomarkers of the metabolic syndrome (MetS) and their prognostic 
significance found in the lower neck and chest.  NCCT Imaging biomarkers, associated with MetS in the chest 
include premature coronary artery calcification, acceleration of large vessel arterial and valvular calcifications 
associated with atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension associated 
with sleep apnea. These easily identified imaging biomarkers have prognostic implications for Major Adverse 
Cardiac Events (MACE). These NCCT chest-imaging biomarkers are likely targets for artificial intelligence algorithms 
to harvest for longitudinal assessment of their individual and multifactorial contributions to chronic disease, MACE 
and mortality. Early recognition and treatment of these common disorders may help improve patient outcomes 
and quality of life while decreasing medical costs. 
Key words (Mesh Terms): Humans, Biomarkers, Prognosis, Metabolic Syndrome, Tomography, X-ray computed, 














AVC    Aortic Valve leaflet Calcification 
CAC   Coronary Artery Calcification  
CT                        Computed Tomography 
DSC Ca++   DeSCending aorta Calcium value  
FR  Framingham Risk Score 
HR  Hazard Ratio 
HU                       Hounsfield unit 
LA  Left Atrium 
LAD Ca++  Left Anterior Descending coronary artery Calcium value, 
LA-MACSA              Left atrial maximal cross-sectional area (mm2) 
LV   Left Ventricle 
MAC   Mitral valve Annulus Calcification 
MACE                     Major adverse cardiovascular event 
MV CA++  Mitral Valve leaflet Calcification 
MetS  Metabolic Syndrome (a.k.a. Syndrome X) 
NCCT                      Non contrast Computed Tomography 
NG-NCCT   Non cardiac Gated, Non-Contrast chest Computed Tomography 
OSA   Obstructive Sleep Apnea 
PH   Pulmonary Hypertension 
mPAP  mean Pulmonary Artery Pressure 
RV   Right Ventricle 














 Cardiovascular disease (CVD) is the number one cause of mortality with an estimated 17.9 million deaths 
worldwide in 2015 (1). This represents an increasing problem for public health  in both  developed and developing 
countries (1). The metabolic syndrome (MetS) is a complex disorder of metabolism which results in an increased risk 
for CVD and Type 2 diabetes (2). It is comprised of a cluster of risk factors including elevated blood pressure, 
dyslipidaemia (lowered high-density lipoprotein (HDL) cholesterol and elevated triglycerides), elevated fasting 
glucose and central obesity (2). The American Heart Association/ ATP III definition of MetS is dependent on three of 
the five risk factors being present (2):  
enlarged waist circumference with population-specific and country-specific criteria; triglycerides ≥ 150 mg/dL, HDL-
c < 40 mg/dL in men and < 50 mg/dL in women, systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 
85 mm Hg and fasting glucose > 100 mg/dL, with the inclusion of patients taking medication to manage 
hypertriglyceridemia, low HDL-c, hypertension and hyperglycemia.(2).   
 All parts of the body are affected by MetS. Recently, Bizino et al, reviewed the role of MRI for the study of 
MetS in the entire body.(3) Work on the gut-brain axis also shows that there is bidirectional signalling between the 
two organs and that the metabolome in the gut, which is influenced by a high fat/refined sugar diet, has critical roles 
in host metabolism, the brain reward system and behavior. (4) Put into more mundane terms, “the comfort foods 
of sugar and fat taste good and the brain wants more than the body needs.” This trend for overindulgence in food 
and sugar filled, and/or alcoholic drinks, spells trouble for the future of medical care expenditures in the developed 
world. 
 The underlying pathophysiology of MetS is related to the induction of low-grade systemic inflammation via 
increased levels of inflammatory cytokines (e.g. IL-6, IL-1 and TNF-), adipokines and leptin, which originate from 
adipocytes or macrophages in the fat tissue. (5) This inflammatory process contributes to atherosclerosis, metabolic 
dysfunction and results in MetS. This increase in inflammation also effects the lung function by activation of 
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fibroblasts, endothelial cells of the lung vessels, airway epithelial and smooth muscle cells. This helps to explain why 
asthma is more severe in obese individuals. (5)  Also, insulin resistance increases in asthmatics as insulin alters airway 
function and structure. (5) Obesity is thus associated with severe asthma induced by low-grade systemic 
inflammation and insulin resistance, which implies that strategies to treat insulin resistance, obesity and systemic 
inflammation could work also for asthma. (5, 6) 
 The prevalence of obesity in adults, defined as BMI >25.0 kg/m2, has increased worldwide from 1980 to 
2013: in women from 29.8 to 38.0 % and in men from 28.8 to 36.9 %.(7) This problem is not limited to the adult 
population, as childhood obesity has also become an increasing problem with important future consequences for 
public health expenditures, morbidity and mortality.(7) Reasons for this increase are high caloric diet, changes of 
diet composition, changes in microbiome of gut, changes in behaviour and lack of physical exercise.(7)  In the 
developing countries, obesity increased from 8.4 to 13.4 in girls and from 8.1 to 12.9% in boys, while the proportion 
of obesity in the developed countries meanwhile is 22.6% in girls and 23.8 in boys.(7) As a consequence, 
cardiovascular dysfunction, diabetes or fatty liver disease with possible progression to end stage liver disease are 
apparent at an early age.(7-9) As the developed world ages, the health effects of obesity (MetS, Type 2 diabetes, 
cardiovascular disease and osteoarthritis of the spine, knees and hips)  will demand an even larger portion  of  future 
public health expenditures.  
   
The purpose of this review is to acquaint radiologists with the current state of the art in the non-cardiac gated, non-
contrast chest computed tomography (NG-NCCT) cardiovascular imaging biomarkers found patients with obesity and 
the metabolic syndrome (MetS) and their prognostic significance.  Our aim is to help identify those persons at risk 
using the metrics from these imaging biomarkers and to then recommend lifestyle interventions (weight reduction, 
increased physical activity and nutritional intervention) and a modification of medical management or surgery to 
improve patient outcomes.(10) 
 
Heart and great vessels  
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 The progression of cardiac and vascular disease takes place over decades and is for the most part 
asymptomatic. Thus, without testing the patient is not aware of the degree of his/her atherosclerotic burden. NG-
NCCT can detect and quantify early heart disease and serve as a prognostic marker, particularly in patients with 
MetS. Madaj and Budoff published a nice summary of the risk stratification that NCCT can provide.(11) Given the 
limited soft-tissue contrast of non-enhanced CT, most prognostic markers are based on the quantification of 
calcification - either as part of vascular arteriosclerosis or valve leaflet calcification. While all cardiac structures are 
affected by cardiac motion, there is increasing evidence that, with newer hardware, and faster gantry rotation times, 
low-dose NG-NCCT cardiac motion is less of a problem for calcification and myocardial scar 
assessment/quantification (Figures 1-4).(12-15) Furthermore, arteriosclerosis is a systemic disease and although the 
association is stronger between atherosclerotic alteration and development of further events in the same organ 
segment (16), assessment of one vascular bed may serve as a proxy for an overall risk marker. However, a significant 
portion of potentially clinically significant cardiovascular findings are currently not mentioned in the written reports, 
particularly by junior radiologists.(17)  
Coronary artery Calcification 
 The most important non-acute finding on NCCT predictive of future major adverse cardiac events is 
coronary artery calcification (CAC) (Figures 2 and 4).  Broad evidence exists regarding the prognostic value of 
coronary artery calcification (CAC) for cardiovascular events (18-22). More importantly, the use of CAC improved 
risk stratification beyond existing, clinical risk scores. This was conclusively shown in the Heinz-Nixdorf RECALL 
included 4,487 subjects without known CAD.  With the addition of  CAC assessment to the Framingham-Risk-Score 
the area under the curve improved from 0.681 to 0.749 (p<0.003) and when CAC was added to the National 
Cholesterol Education Panel ATP III categories the area under the curve improved from 0.653 to 0.755 (18).  CAC 
was a much stronger predictor of risk than carotid intima-media thickness, high-sensitivity C reactive protein and 
the ankle-brachial index (19). Further results from the MESA study showed that CAC improves risk assessment in 
individuals with family history (19). Consequently, CAC assessment has been incorporated into many clinical 
guidelines for risk stratification. Depending on the guideline used, CAC is considered an appropriate test to 
perform in asymptomatic adults at intermediate risk for heart disease. These patients are defined by having a 10% 
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to 20% 10-year risk or having a Systemic Coronary Risk evaluator (SCORE) (23) risk stratification value range of 5% - 
10%, low-risk individuals with a family history of premature disease and all diabetic patients 40 years or older are 
also candidates for this test. (24-26) Budoff and colleagues (22) have recently shown that in the MESA cohort 
(N=6814) (https://www.mesa-nhlbi.org/Calcium/input.aspx ) for each doubling of CAC there was a 14% increase in 
CVD risk. They concluded that CAC is highly associated with MACE and is this gated non contrast CT biomarker was 
found to be independent of standard risk factors (Supplementary Table S1).(22) 
................................................................................................................................................ 
 Evidence based guidelines for the use of CAC are based on publications using cardiac-gated CT. This is 
because CAC has a high density and is sensitive to motion artefacts leading to false CAC values (27). New 
technology of multi-detector computed tomography scanners with faster gantry rotation times and thinner 
detector row widths allow for thinner slices with a reduction in partial volume effects. These changes in hardware 
now allow for more exact and reliable measurement of CAC on non-gated NCCT scans (NG-NCCT). In a study by Wu 
et al (28) on 483 patients showed excellent correlation of Agatston CAC scores between a dedicated cardiac gated 
non-contrast CT for calcium scoring (16 slice multidetector, 3.0 mm slice thickness) and a low dose NG-NCCT ( 16 
slice multidector,  0.75mm slice thickness )performed for lung cancer screening (Figure 1). In their cohort of NG-
NCCT patients the average heart was 61 beats per minute. They did not assess the importance of potential heart 
rate dependent motion artifact that may limit the accurate quantification of calcium score using non gated CT 
protocols.(28) They found an intraclass correlation coefficient of 0.95 for the agreement between the scores on 
low-dose NG-NCCT versus the respective routine cardiac-gated CT for CAC in this one observer study. In a study by 
Kim et al., where 128 patients underwent both non-gated low dose lung cancer screening and ECG-gated CAC 
scanning, an accuracy of 90% was observed for CAC>0 on the gated CAC scan and the absolute CAC scores 
correlated well (r=0.89) (29). In a meta-analysis of 661 subjects (3 separate studies) performed in 2013, Xie et al 
convincingly showed that, when the Agatston Score at non-gated low dose NCCT was compared with the gold 
standard of routine cardiac gated CT performed for CAC scoring, the pooled correlation coefficient was 0.94 
(95%CI: 0.89-0.96).  These data are confirmative of the newly available scatter plot from Wu et al(28) (Figure 1) 
showing a R2 of 0.95 between Agatston scores as derived from NG-NCCT versus cardiac gated CT. 
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 While the Agatston score as a continuous measurement has been established for formal CAC assessment, 
the development of visual scores for CAC categorization is essential in order to provide the chest radiologist with a 
simple technique that is less time consuming. Several studies have been performed showing that either a visual-
qualitative assessment or a visual ordinal scale can be used for reliable and accurate risk assessment as compared 
to Agatston score (30-32). But more importantly, both Agatston score and/or a visual CAC assessment from NG-
NCCT have prognostic value for cardiovascular events and overall mortality. In detail, a study performed by Mets et 
al in 3,648 lung cancer screening patients using an automatically derived Agatston score from NG-NCCT in a risk 
prediction model found overall good discrimination (AUC 0.71) with an event frequency of 12.2% vs 4.0% in the high 
vs. low risk groups, respectively.(33)          In the ECLIPSE trial Williams et al found that CAC was increased in patients 
with chronic obstructive pulmonary disease and was associated with an increased risk of death.(34) In the National 
Lung Screening Trial assessing 1,442 patients (35), an Agatston scores of 1-100, 101-1000, and >1000 had HR of 1.27, 
3.57, and 6.63 as derived from NG-NCCT and compared to an Agatston score of 0. Interestingly, in a case-control 
study authored by Hughes-Austin et al. in which both  ECG-gated 3 mm and non-gated 6 mm CT scans were available, 
the predictive value of the Agatston score for mortality where similar.(36) Focusing on visual assessment, Shao et al 
showed in a single centre study that there is no significant difference in the discriminative power of visual CAC 
assessment vs. Agatston score (AUC: 0.80, 0.81).(37) Most evidence exist for a visual assessment using an ordinal 
CAC scoring system categorizing from 0-12 or 0-30 based upon visual estimation (Table 1). The study of Shemesh et 
al. including 8,782 smokers with 72 months mean follow up showed that this simple ordinal system was strongly 
predictive for cardiovascular death (32) and further confirmed by Blair et al. to be  of similar predictive value  as the 
Agatston score (31) (Table 2).  Gonzales et al have recently shown that automated detection of Agatston scores can 
be derived from NG-NCCT exams.(38) Thus, in a common guideline, the Society of Cardiovascular Computed 
Tomography (SCCT) and the Society of Thoracic Radiology (STR) recommend “the incorporation of CAC into all non-
gated non-contrast chest examination reports” since it “in the treatment of coronary artery disease“.(39) 
 It is very clear that coronary artery calcium can be reliably detected on NG-NCCT and that either ordinal 
scoring methods or quantification of the NG-NCCT Agatston score are highly correlated (within 10%) with those 
cardiac gated non-contrast CT exams that are performed only for CAC scoring.  An argument can be made that the 
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CAC score value obtained using current state of the art multidetector NG- NCCT of the chest, performed for any 
reason, are a good proxy for a dedicated CAC scoring CT. 
    
Aortic calcification 
 The thoracic aorta is another important vascular bed imaged on a standard chest CT. As compared to the 
coronary arteries, the assessment thoracic aorta calcification (TAC) less standardized but also less effected by cardiac 
motion. In a retrospective study by Jairam et al. found good predictive value for cardiovascular events when including 
visual assessment of TAC (HR: 0.37, p<0.001) into a larger predicting model.(40) Similar results were observed in the 
Heinz Nixdorf RECALL study (41), where TAC together with other CT-derived parameters improved the prediction of 
events over the Framingham Risk Score and CAC (AUC: 0.749 to 0.764; p=0.01). In contrast, Kim et al found in subjects 
from the MESA study without CAC (n=3,415) that TAC was associated to cardiovascular events and all-cause 
mortality, but this association attenuated after adjustment for cardiovascular risk factors.(42) Similarly, in the 
Framingham Heart Study TAC provided no incremental value above risk factors for the prediction of events.(43) 
Thus, TAC is a prognostic marker, but its incremental value to traditional risk factors and other CT-findings, particular 
to CAC remain controversial.  
Valvular Calcification  
 The most common valve affected by calcification is the aortic valve. The aortic valve calcification (AVC) can 
vary by its degree and/or by its location and can lead to aortic stenosis. The degree of stenosis is increasing with AVC 
extent, while calcification of the peripheral left-posterior and the central right-left commissural leaflets is particularly 
correlated with mean and peak gradient increases across the aortic valve.(44) The underlying pathophysiology is 
complex and integrates lipids, the renin-angiotensin system, inflammation, signalling pathways, and genetic 
predisposition.(45) Also, a strong linkage to visceral obesity has been described leading the neologism ‘valvulo-
metabolic’ risk.(46) Further, AVC shares common risk factors with arteriosclerosis; hence, patients with AVC had 
more frequently coexisting presence of coronary plaque and had a greater extent of coronary plaque burden (6.4 vs 
1.8 segments for patients with and without AVC, P<0.001) as described in a study of 357 subjects undergoing cardiac 
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CT. (47) Interestingly, AVC was more strongly associated with calcified (OR: 5.2, p=0.004), then with mixed (OR: 3.2, 
p=0.02) or non-calcified plaque (P=0.96). Several studies have been performed regarding the prognostic value of 
AVC for cardiovascular events and all-cause mortality. Although AVC showed a prognostic value in univariate 
analysis, it attenuated in most studies after adjustment for traditional risk factors and after further adjustment for 
CAC and/or TAC.(43, 48-50) 
Annular Calcification 
 The annulus of the mitral valve is most commonly calcified. Mitral annular calcification (MAC) is a chronic 
degenerative process in the fibrous base of the mitral valve and more commonly affects the posterior annulus than 
the anterior annulus. (51) Traditionally, MAC is assessed using echocardiography and several studies using this 
technology showed independent association of MAC with cardiac events.(52, 53) Given a good relationship in MAC 
between echocardiography and CT (54), MAC was also a good predictor for cardiovascular events if assessed by CT 
(55, 56). In the Northern Manhattan Study (n=1,955) (55), MAC prevalence was 27%, while severe MAC (>4mm 
thickness) was observed in 13%. Presence of MAC was associated with myocardial infarction (HR: 1.75) and cardiac 
death (HR: 1.53) and these associations became stronger if using severe MAC as the predictor (HR: 1.89 and 1.81; 
respectively). In this cohort, but also in a cohort with atrial fibrillation, MAC was not significantly associated with 
cerebrovascular events. (55, 56)    
 Caseous calcification of the mitral valve is a rare form of MAC. The contents of the hollowed out cavity in 
the mitral valve annulus is composed of a mixture of calcium, fatty acids, and cholesterol that has a ‘‘toothpaste-
like’’ texture. This commonly presents as an intracardiac mass at echocardiography. There is limited evidence 
regarding the prognostic value of caseous calcification of the mitral annulus. In a literature review of 1,502 articles, 
Dietl et al. identified a total of 130 patients with caseous calcification of the mitral annulus reported in 86 
publications. The prevalence of cerebrovascular events was higher in patients with caseous calcification of the mitral 
annulus than with simple MAC (19% vs 12%, respectively; p=0.02).  
Atrial and Ventricular size 
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 There is a large body of evidence that MetS carries an increased risk of left ventricle (LV) hypertrophy, left 
atrial (LA) enlargement, systolic and/or diastolic dysfunction, arrhythmias and interstitial myocardial fibrosis.  MetS 
is also associated with increased LV mass and LV diastolic dysfunction.(57, 58)  (Aijaz et al 2008, Ladeiras-Lopes et 
al. 2018, Shah et al. 2013) CT can be useful for assessing cardiac chambers to determine their size, shape and 
thickness. Cardiac gated CT scans can usually be obtained during diastole for CAC scoring and coronary angiography, 
as this phase of the cardiac cycle has the least motion. While chamber assessment is relatively simple for gated, 
contrast-enhanced CT scans given existing software tools, NG-NCCT exams are more challenging and an area-based 
approach has been proposed. Schlett et al. showed that an area-based measurement for LV on axial, non-contrast 
enhanced CT images correlates well with LV volume, mass and size (r=0.68; r=0.73; r=0.82).(59) Similar correlations 
were observed for the left atrium.(60) In the MESA cohort, such area-based LV measurement of non-contrast CT 
scans is a predictor of incident heart failure events (HR 1.15; 95%CI 1.11-1.20) beyond traditional risk factors and 
CAC score; but also for CHD events (HR 1.07; 95%CI 1.03-1.10). As RV and LV contraction is usually synchronous, the 
RV/LV diameter and volume ratios have been used in NG-NCCT studies to assess RV dilation and dysfunction in 
response to increased RV afterload. (Henzler et al 2012, Mansencal et al. 2005) A limited number of reports indicate 
that RV hypertrophy may parallel alterations in LV structure and function in the setting of systemic hypertension, 
obesity and diabetes. (Chahal et al 2012) All the components of MetS (increased blood pressure, abdominal obesity, 
increased fasting glucose level and dyslipidemia) may induce right ventricular remodelling by several hemodynamic 
and non-hemodynamic mechanisms. (Tadic et al. 2013)  Increasing evidence suggests that in pulmonary 
hypertension (PH) RV dysfunction is associated with various components of MetS, such as insulin resistance, 
hyperglycemia, and dyslipidemia. (Talati et al. 2015)  
 Regarding LA assessment, an enlarged size was associated with a 3- to 5-fold increase risk for ACS and 
provided incremental value for predicting ACS when added to the CT finding of indeterminate coronary artery 
stenosis in a population with acute chest pain presenting to the ED. (61)  In the Heinz-Nixdorf Recall Study (62), LA 
size had prognostic value (HR 1.48), which remained significant after adjustment for traditional risk factors (HR 
95%CI: 1.09-1.43) and after adjustment for  traditional risk factors plus CAC (HR 95%CI: 1.07-1.40) (Table 2). 
Prognostic value of LA size was similar for different endpoints (coronary event: HR: 1.21; stroke: 1.31; CV death: 
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1.33). LA size also remained associated with cardiovascular events independent of other CT non-coronary 
findings.(41) Recently Jivraj et al have shown in 165 patients with right heart catheterization proven pulmonary 
hypertension (PAP > 45 mm Hg) and capillary wedge pressures (43 patients - PCWP > 15 mm Hg, 122 patients 
PCWP < 15 mm Hg) that left atrial maximal cross-sectional area (LA-MACSA) measured from NG-NCCT (LA-MACSA > 
2400mm2, P<0.001) had a 44% sensitivity and 93% specificity for pulmonary hypertension from left heart disease.(63) On NG-
NCCT studies the images may not reveal the true ventricular morphology because the phase of the cardiac cycle is 
unknown. However, a few studies have reported good sensitivity and specificity (both >68%) of standard axial, 
non-gated chest CT for cardiomyopathies. (64)  
Left ventricle 
 The left ventricle size (volume and in-plane area) can be estimated from NCCT chest exams. Bhatt and 
colleagues (65) have created an automated process for generating the expected ventricular sizes from NG-NCCT 
chest exams by comparing these studies to ultrasound and cardiovascular MRI exams that show the ventricular 
volumes and wall thickness (Supplemental Figure 1). The assessment of ventricular volume and wall thickness is 
easier if the patient is anemic, as the ventricular chambers are seen to be of lower Hounsfield unit density than the 
walls. The presence of prior left ventricular myocardial infarction is also easily determined by the presence of a low 
density scar (Figure 3). These are typically seen in the subendocardial regions of the wall and may be transmural.  
 Recently Kockelkoren et al published their data from routine NG-NCCT exams on patients that were studied 
for non-cardiovascular disease (Tables 3 and 4). This was derived from a rather homogeneous population of 
Caucasians in the United Kingdom. This group of researchers created a simple to use ordinal grading scale for the 
determination of future major adverse cardiac events (MACE) (Table 3) and have a computational model for the 
likelihood of a major cardiac event within 5 years that is based on a best fit multivariable regression model 
(Supplementary Tables S2, S3). The parameters include: age, male gender, indication for exam, left anterior 
descending coronary artery calcium (LAD Ca++) value, mitral valve leaflet calcification (MV CA++) value, descending 
aorta calcium value (DSC Ca++), and the maximum transverse diameter (cm) of the heart. 
Epicardial Fat 
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 In their study of 3,630 subjects from the Heinz-Nixdorf  Recall Study, Mahabadi et al(41) found that the 
epicardial fat volume (HR: 1.15, 95% C.I 1.01-1.30, p value 0.03),  was an imaging biomarker predictive of myocardial 
infarction, stroke and cardiovascular death (Table 5). In their systematic review, Bertaso et al found that the 
heterogeneity of the studies limits the conclusions that can be drawn from using this metric. They found that this 
visceral fat deposit is highly correlated with obesity, diabetes mellitus, age and hypertension. Manno et al showed 
that epicardial fat thickness at ultrasound was correlated with higher LDL cholesterol.(66) In their study from 2018, 
Hedgire et al show that perivascular fat stranding, seen on coronary CT angiography is associated with high risk 
clinical features and they suggest that fat stranding is a potential imaging biomarker of high-risk and/or ruptured 
atherosclerotic plaques.(67) Hartiala et al found no evidence that increased epicardial fat volume was independently 
associated with pre-clinical atherosclerosis.(68) Instead, they found that epicardial fat volume was primarily 
associated with BMI and waist circumference.(68) Furthermore, there is increasing evidence that fat quality rather 
fat volume may play a role in the association to CVD. (69) 
Pulmonary artery diameter predicts pulmonary hypertension 
 Sleep disordered breathing (sleep apnea) is an important cause of pulmonary hypertension.(70)  
Obstructive Sleep Apnea (OSA) is caused by the increased collapsibility of the upper airway from loss of muscle tone 
and a decrease in the effective orifice from fat deposition in the tongue and surrounding pharynx during sleep.(71) 
This results in decreased or absent airflow and hypoxia. These episodes are usually terminated by a brief arousal 
from sleep and resulting in sleep deprivation for subjects with MetS.(72)  Over many years, these apneic episodes 
lead to sleep fragmentation and altered cognitive function. (73) These episodes of hypoxia are associated with 
pulmonary artery vasoconstriction and can lead to permanent changes in PA size (Figure 5).(74) Corson et al studied 
175 subjects with right heart catheterization (RHC)  proven pulmonary hypertension (PH), 16  normal patients with 
proven normal  mean pulmonary artery pressures (mPAP) and 114 subjects without known mPAP and found a 
sensitivity of the criterion “mean pulmonary artery diameter at the level of the bifurcation  >29mm” was 0.89 (95% 
C.I. 0.84-0.93) and a specificity of 0.83 (95%CI: 0.76-0.90).(75) Truong et al  studied 706 “healthy cohort” subjects in 
the Framingham Heart Study using cardiac gated NCCT and found a 90th percentile cut-off value of 28.9 mm in men 
and 26.9 mm in women.(76) Pulmonary artery diameter is an important clue that may indicate pulmonary 
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hypertension from any cause (77); and in the setting of obesity or MetS an enlarged PA can then be used to alert the 
imager and clinician to the possibility for OSA.  Instituting treatment with Continuous Positive Airway Pressure (CPAP) 
can significantly improve the length and quality of life for these individuals. 
Radiation dose and safety using NG-NCCT for the diagnosis of MetS 
 We are not proposing to use NCCT for the diagnosis of MetS or obesity. From studies performed for other 
indications, the imaging physician can also make inferences about the metabolic milieu of that subject based on the 
multiple imaging findings discussed in this review. For the most, part low dose chest CT protocols are very low 
contributors to the medical radiation any patient receives over the course of their lifetime.(78)  Each scan delivers 
between 0.5 and 5 mSv depending on the patient size, use of dose lowering reconstruction methods and automatic 
exposure control (limit mAs).(79) 
Conclusion  
 The beauty of non-gated, non-contrast computed of the chest is that quantitative assessment of Hounsfield 
unit density, contour and volume of many organs can be assessed longitudinally and correlated to patient outcomes. 
This differs substantially from contrast enhanced CT data, because there is no iodinated contrast material 
confounding the density measurements. There are easy to access imaging biomarkers associated with obesity, 
atherosclerotic disease and MetS that are routinely seen on these exams. The most important one found on NG-
NCCT is coronary artery calcification. Various models combining clinical and imaging data have been shown to have 
prognostic significance for Major Adverse Cardiac Events. Thus, these exams are a virtual treasure trove of 
quantitative imaging biomarker information available for retrospective analysis to create survival models (training 
sets) that can be applied prospectively to test sets and validated with external data sets. These big data can be added 
to radiomic feature analysis, convolutional neural networks and/or added to deep neural networks without any user 
defined features to create better survival models that can be used to help design personalized medical interventions 
aimed at prolonging quality life expectancy. 
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Legend Figure 1:  Data from Wu et al (28) in a study comparing Agatston Calcium Scores on non-cardiac gated, 
non-contrast low dose CT (LDCT) performed for lung cancer screening to standard cardiac gated, non-contrast 
computed tomography (NCCT) in 513 consecutive cases. This shows excellent correlation between these two ways 
to quantify Agatston coronary artery calcification scores (R2=0.95). They found a systematic under quantification 
of CAC using LDCT (y intercept = -12.1). Thus, any coronary artery calcification found at LDCT is worthy of 
quantification. This can be performed either by ordinal scoring or using post processing to obtain the non-cardiac 
gated LDCT Agatston score. (Scatter plot of the raw data made expressly for this article by Ming-Ting Wu, M.D.) 
Legend Figure 2:  Non gated, non-contrast computed tomography of the chest with globular calcification of an 
atherosclerotic plaque at the origin of the left anterior descending coronary artery (arrow head). 
Legend Figure 3: Non-gated, non-contrast computed tomography of the chest coned down to the heart (A) axial 
and (B) short axis reconstruction showing a fibrofatty subendocardial scar (arrows) in the left ventricular septum, 
inferior and inferolateral walls from an old myocardial infarction in the right coronary artery vascular territory.  
Note the presence of hepatic steatosis as well (A) with a liver density of 35 Hounsfield units (ROI -Region of 
interest). 
Legend Figure 4:  45 year old Caucasian male with(A) borderline evidence  for low iodine organification in the 
thyroid with a thyroid density of 64 ( Normal range 80-120 HU) (B)  non gated Agatston score of 2 is at least in the 
79th percentile for age and sex. There was hepatic steatosis as well (C) with a liver density of 42.9 HU. The 
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paraspinous muscle density was low measuring 33.8 HU at the T12 level (Normal range 5-60HU, from unpublished 
data (Tsuchiya et al, submitted)). This constellation of findings is the imaging equivalent of the clinically defined 
Metabolic Syndrome and suggests both glucose intolerance and an increase in overall inflammatory cytokines due 
to the low paraspinous muscle density. 
Legend Figure 5: Pulmonary trunk measured at the largest part of the right main pulmonary artery is 4.0 cm (white 
line). This is abnormal and is suggestive of the possibility of pulmonary hypertension/pulmonary arterial 
hypertension. In an obese individual a common cause is sleep disordered breathing (sleep apnea) which can be 
treated with a night time Continuous Positive Airway Pressure (CPAP) mask. 
Legend Supplemental Figure 1: Automatic segmentation of the left and right ventricular cavities from non contrast 
non cardiac gated chest CT exams using the method of Bhatt et al (65), (A) axial chest CT with the estimated left 
ventricle cavity in light red  and the estimated left ventricular wall in dark red, with the estimated right ventricle in 
blue, (B) sagittal non contrast CT showing the  estimated left  ventricle in red and the estimated right ventricle in 
blue. (C) coronal chest CT showing the estimated left ventricle in red and the estimated right ventricle in blue, (D) 
Entire volume of left ventricle in red and right ventricle in blue. 
Legend Table 1: Importance  of coronary artery calcification found on non-cardiac gated chest computed 
tomography in patients that smoke cigarettes (table modified from Shemesh et al) (80) Practical comments for 
chest radiologists showing that the larger ordinal coronary artery calcium score is associated with an increased risk 
of Major Adverse Cardiac Events. (This table is modified from Shemesh et al (80)) Abbreviations: CAC- coronary 
artery calcium score; Visual Score (Likert Scale range from 0-12); CAD- coronary artery disease, PVD- peripheral 
vascular disease; 
Legend Table 2: Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are 
reflective of individual biology and the metabolic syndrome. (Abbreviations: n- number affected. N=total in study) 
Legend Table 3: Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N= 
2124) (81). This type of analytic approach to documenting vascular calcifications was first used by Jairam et al in 
2014 (40). 
Legend Table 4: Hazard Ratios for the most significant model parameters for determining cardiovascular risk from 
contrast enhanced, non-gated chest CT exams from the PROVIDI study (N=10,410)   (40). 
 
Legend Table 5: Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 
3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorff Recall Study. (41) and their adjusted Hazard 
Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk 
Score, CAC- Coronary artery Agatston Score,)  
 
Legend Table S1: Multi-Ethnic Study of Atherosclerosis  (MESA) results from Budoff et al(22)  modified from Table 
2 in the original publication, showing the ten year event rate of major adverse cardiac events based simply off of 
the gated CT chest coronary artery Agatston calcium scores. These event rates are not adjusted for any clinical risk 
factors. These data show the effects of CAC transcend age related changes; in that more CAC is worse than simply 
being old. The   Chinese and Caucasian were less affected by CAC than African-Americans and Hispanics. 
Legend Tables S2 and S3: Kockelkoren (81) Scottish heart study risk 10 year estimated risk model (Table S2) and 




























Figure 1:  Data from Wu et al (28) in a study comparing Agatston Calcium Scores on non-cardiac gated, non-
contrast low dose CT (LDCT) performed for lung cancer screening to standard cardiac gated, non-contrast 
computed tomography (NCCT) in 483 cases. This shows excellent correlation between these two ways to quantify 
Agatston coronary artery calcification scores (R2=0.95). They found a systematic under quantification of CAC using 
LDCT (y intercept = -12.1). Thus, any coronary artery calcification found at LDCT is worthy of quantification. This 
can be performed either by ordinal scoring or, as in this study, using post processing to obtain the non-cardiac 

















Legend Figure 2:  Non gated, non-contrast computed tomography of the chest with globular calcification of an 








Legend Figure 3: Non gated, non-contrast computed tomography of the chest coned down to the heart (A) axial 
and (B) short axis reconstruction showing a fibrofatty subendocardial scar (arrows) in the left ventricular septum, 
inferior and inferolateral walls from an old myocardial infarction in the right coronary artery vascular territory.  




















Legend Figure 4:  45 year old Caucasian male with(A) borderline evidence  for low iodine organification in the 
thyroid with a thyroid density of 64 ( Normal range 80-120 HU) (B)  non gated Agatston score of 2 is at least in the 
79th percentile for age and sex. There was hepatic steatosis as well (C) with a liver density of 42.9 HU. The 
paraspinous muscle density was low measuring 33.8 HU at the T12 level (Normal range 5-60HU, from unpublished 
data (Tsuchiya et al, submitted)). This constellation of findings is the imaging equivalent of the clinically defined 
Metabolic Syndrome and suggests both glucose intolerance and an increase in overall inflammatory cytokines due 
to the low paraspinous muscle density. 
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Legend Figure 5: Pulmonary trunk measured at the largest part of the right main pulmonary artery is 4.0 cm (white 
line). This is abnormal and is suggestive of the possibility of pulmonary hypertension/pulmonary arterial 
hypertension. In an obese individual a common cause is sleep disordered breathing (sleep apnea) which can be 














Legend Supplemental Figure 1: Automatic segmentation of the left and right ventricular cavities from non contrast 
non cardiac gated chest CT exams using the method of Bhatt et al (65), (A) axial chest CT with the estimated left 
ventricle cavity in light red  and the estimated left ventricular wall in dark red, with the estimated right ventricle in 
blue, (B) sagittal non contrast CT showing the  estimated left  ventricle in red and the estimated right ventricle in 
blue. (C) coronal chest CT showing the estimated left ventricle in red and the estimated right ventricle in blue, (D) 
























Prognosis  Recommendation Comment 






The presence of chronic 
obstructive CAD is very 
unlikely, life style changes 
Might be false 
negative  





the visual score is 
less sensitive  
in subjects with 
low CAC burden 
Mild CAC 1-100 1-4 Mildly 
increased 
risk for CV 
event 
Consider further coronary 
evaluation and primary 
preventive treatment 
according to the patient 
global risk, life style changes 





101-400 5-7 Mildly 
increased 
risk of CV 
event 
Consider further coronary 
evaluation and primary 
preventive treatment 
according to the patient 
global risk and clinical 
manifestations; in patients 
with Framingham risk 
intermediate and above 
(≥10% in 10 years) statin 











In asymptomatic subjects, 
consider further coronary 
evaluation by stress ECG, 
stress echo or SPECT imaging 
to R/O obstructive CAD; statin 
therapy should be highly 
considered. 
Mostly prevalent 
in old patients  
and in those with 
clinical CAD, PVD 
and renal failure 
Table 1: Importance  of coronary artery calcification found on non-cardiac gated chest computed tomography in 
patients that smoke cigarettes (table modified from Shemesh et al) (80) Practical comments for chest radiologists 
showing that the larger ordinal coronary artery calcium score is associated with an increased risk of Major Adverse 
Cardiac Events. (This table is modified from Shemesh et al (80)) Abbreviations: CAC- coronary artery calcium score; 




















Non contrast,  
Chest CT finding 























diameter of heart 
    Leiner article 




















2,146 ± 275 
[3389/3630] 
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at Pul Art 
bifurcation 
35.5 ± 4.0 
[3389/3630] 






















































Legend Table 2: Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are 






































artery calcification  
 none 1 or 2 calcified 
plaques limited to 
2 or fewer images 
Greater than 2 focal 
plaques or calcification 
extending for more 
than 2 slices 
Fully calcified  
coronary artery 
extending for more 
than 3 slices 
Descending Thoracic 
Aorta Calcification 
none Less than or equal 
to 3 focal calcified 
plaques 
4-5 focal calcified 
plaques or one plaque 
extending for 3 or more 
slices 
More than 5 focal 
calcified plaques or 2 
plaques extending 
beyond 3 slices 
Mitral valve leaflet 
Calcification 







Legend Table 3: Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N= 






















Model feature Hazard Ratio P value 
Male 1.41 <0.001 
Descending Aorta Calcification 1.45 <0.001 
Mitral Valve Calcification 1.25 <0.001 
LAD Calcification 1.11 <0.003 
(Maximum Transverse Cardiovascular diameter in cm  -
11cm)2 
1.03 <0.001 
Age 1.03 <0.001 
Legend Table 4: Hazard Ratios for the most significant model parameters for determining cardiovascular risk from 























Table 5  
 
Model feature Hazard Ratio 
Adjusted for FR score, CAC 




Left atrial index 1.21 
(1.07-1.36) 
0.002 
Left ventricular index 1.15 
(1.02-1.29) 
0.02 
Epicardial Fat Volume 1.14 
(1.01-1.28) 
0.04 
Presence of Thoracic Aortic Calcification 1.14 
(0.83-1.56) 
0.43 




Aortic Valve Calcification 1.01 
(0.72-1.40) 
0.98 
Diameter of the Descending thoracic Aorta 0.98 
(0.84-1.15) 
0.84 





Legend Table 5: Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 
3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorff Recall Study. (41) and their adjusted Hazard 
Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk 
















































































Ages 75-85 5.6 14.3 18.1 24.7 
African-
American 
3.9 7.7 14.7 24.5 






2.7 7.7 13.4 19.9 
Female 2.8 7.3 10.6 19.0 
Male 3.0 8.0 14.4 18.2 





2.8 7.4 12.9 16.5 
Ages 45-54 1.7 3.8 15.4 16.2 
Caucasian 2.4 7.3 10.8 16.2 
Ages 65-74 4.2 8.3 11.8 15.0 
Chinese 1.3 4.7 8.3 13.1 
 
Legend Table S1: Multi-Ethnic Study of Atherosclerosis  (MESA) results from Budoff et al(22)  
modified from Table 2 in the original publication, showing the ten year event rate of major 
adverse cardiac events based simply off of the gated CT chest coronary artery Agatston 
calcium scores. These event rates are not adjusted for any clinical risk factors. These data 
show the effects of CAC transcend age related changes; in that more CAC is worse than 
simply being old. The   Chinese and Caucasian were less affected by CAC than African-










Supplemenatary Table S2: 
 
Kockelkoren risk  model (81) 
 
 Predicted vs Observed 10 year cardiovascular risk  
Risk Group  10y Risk: Radiological risk score  
Low risk group (<10% risk)  
No. of patients n (%)  200 (9)  
Observed Kaplan-Meier risk (%)  9.8%  
Intermediate risk group (10-20% risk)  
No. of patients n (%)  523 (25)  
Observed Kaplan-Meier risk (%)  18.8%  
 38 
High risk group (>20% risk)  
No. of patients n (%)  1401 (66)  
Observed Kaplan-Meier risk (%)  36.5%  
* 10y observed CVD risk was obtained by extrapolating the cumulative baseline hazard 
function  
 
Legend Tables S2 and S3: Kockelkoren(81) Scottish heart study risk 10 year estimated risk 
model( Table S2) and the equation used to derive the 5 year risk score (Table S3) 
 
 
Supplementary Table S3 
 
Model parameters (81) 
 
5-year cardiovascular disease event risk (%) = [1-0.88(exp[A-2.16])] x 100% 
  
A = (0.027 x Age) + (0.34 if male gender) – (0.33 if CT-indication hematological malignancies) – (0.34 if CT-indication 
mediastinal abnormalities) – (0.27 if CT-indication suspicion pulmonary malignancy) + (0.034 if CT-indication 
suspicion pulmonary embolism) – (0.30 if other CT-indication) + (0.10 x score [LAD calc]) + (0.22 x score [MV calc]) 
+ (0.37 x [DSC calc]) + (0.02 x [Cardiac diameter* - 11cm]2)  
* Cardiac diameters below 11 cm get value “0”, from higher diameters subtract 11 and square the resulting value. 
Legend Tables S2 and S3: Kockelkoren(81) Scottish heart study risk 10 year estimated risk model( Table S2) and the 
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Abstract 
There are physiological consequences of overeating that can lead to increased morbidity and mortality. Purpose of 
this review article is to acquaint the reader with the current state of the art in the non-cardiac gated, non-contrast 
chest Computed Tomographic (NCCT) imaging biomarkers of the metabolic syndrome (MetS) and their prognostic 
significance found in the lower neck and chest.  NCCT Imaging biomarkers, associated with MetS in the chest 
include premature coronary artery calcification, acceleration of large vessel arterial and valvular calcifications 
associated with atherosclerosis, and pulmonary arterial enlargement from pulmonary hypertension associated 
with sleep apnea. These easily identified imaging biomarkers have prognostic implications for Major Adverse 
Cardiac Events (MACE). These NCCT chest-imaging biomarkers are likely targets for artificial intelligence algorithms 
to harvest for longitudinal assessment of their individual and multifactorial contributions to chronic disease, MACE 
and mortality. Early recognition and treatment of these common disorders may help improve patient outcomes 
and quality of life while decreasing medical costs. 
Key words (Mesh Terms): Humans, Biomarkers, Prognosis, Metabolic Syndrome, Tomography, X-ray computed, 













AVC    Aortic Valve leaflet Calcification 
CAC   Coronary Artery Calcification  
CT                        Computed Tomography 
DSC Ca++   DeSCending aorta Calcium value  
FR  Framingham Risk Score 
HR  Hazard Ratio 
HU                       Hounsfield unit 
LA  Left Atrium 
LAD Ca++  Left Anterior Descending coronary artery Calcium value, 
LA-MACSA              Left atrial maximal cross-sectional area (mm2) 
LV   Left Ventricle 
MAC   Mitral valve Annulus Calcification 
MACE                     Major adverse cardiovascular event 
MV CA++  Mitral Valve leaflet Calcification 
MetS  Metabolic Syndrome (a.k.a. Syndrome X) 
NCCT                      Non contrast Computed Tomography 
NG-NCCT   Non cardiac Gated, Non-Contrast chest Computed Tomography 
OSA   Obstructive Sleep Apnea 
PH   Pulmonary Hypertension 
mPAP  mean Pulmonary Artery Pressure 
RV   Right Ventricle 












 Cardiovascular disease (CVD) is the number one cause of mortality with an estimated 17.9 million deaths 
worldwide in 2015 (1). This represents an increasing problem for public health  in both  developed and developing 
countries (1). The metabolic syndrome (MetS) is a complex disorder of metabolism which results in an increased risk 
for CVD and Type 2 diabetes (2). It is comprised of a cluster of risk factors including elevated blood pressure, 
dyslipidaemia (lowered high-density lipoprotein (HDL) cholesterol and elevated triglycerides), elevated fasting 
glucose and central obesity (2). The American Heart Association/ ATP III definition of MetS is dependent on three of 
the five risk factors being present (2):  
enlarged waist circumference with population-specific and country-specific criteria; triglycerides ≥ 150 mg/dL, HDL-
c < 40 mg/dL in men and < 50 mg/dL in women, systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 
85 mm Hg and fasting glucose > 100 mg/dL, with the inclusion of patients taking medication to manage 
hypertriglyceridemia, low HDL-c, hypertension and hyperglycemia.(2).   
 All parts of the body are affected by MetS. Recently, Bizino et al, reviewed the role of MRI for the study of 
MetS in the entire body.(3) Work on the gut-brain axis also shows that there is bidirectional signalling between the 
two organs and that the metabolome in the gut, which is influenced by a high fat/refined sugar diet, has critical roles 
in host metabolism, the brain reward system and behavior. (4) Put into more mundane terms, “the comfort foods 
of sugar and fat taste good and the brain wants more than the body needs.” This trend for overindulgence in food 
and sugar filled, and/or alcoholic drinks, spells trouble for the future of medical care expenditures in the developed 
world. 
 The underlying pathophysiology of MetS is related to the induction of low-grade systemic inflammation via 
increased levels of inflammatory cytokines (e.g. IL-6, IL-1 and TNF-), adipokines and leptin, which originate from 
adipocytes or macrophages in the fat tissue. (5) This inflammatory process contributes to atherosclerosis, metabolic 
dysfunction and results in MetS. This increase in inflammation also effects the lung function by activation of 
fibroblasts, endothelial cells of the lung vessels, airway epithelial and smooth muscle cells. This helps to explain why 
asthma is more severe in obese individuals. (5)  Also, insulin resistance increases in asthmatics as insulin alters airway 
function and structure. (5) Obesity is thus associated with severe asthma induced by low-grade systemic 
inflammation and insulin resistance, which implies that strategies to treat insulin resistance, obesity and systemic 
inflammation could work also for asthma. (5, 6) 
 The prevalence of obesity in adults, defined as BMI >25.0 kg/m2, has increased worldwide from 1980 to 
2013: in women from 29.8 to 38.0 % and in men from 28.8 to 36.9 %.(7) This problem is not limited to the adult 
population, as childhood obesity has also become an increasing problem with important future consequences for 
public health expenditures, morbidity and mortality.(7) Reasons for this increase are high caloric diet, changes of 
diet composition, changes in microbiome of gut, changes in behaviour and lack of physical exercise.(7)  In the 
developing countries, obesity increased from 8.4 to 13.4 in girls and from 8.1 to 12.9% in boys, while the proportion 
of obesity in the developed countries meanwhile is 22.6% in girls and 23.8 in boys.(7) As a consequence, 
cardiovascular dysfunction, diabetes or fatty liver disease with possible progression to end stage liver disease are 
apparent at an early age.(7-9) As the developed world ages, the health effects of obesity (MetS, Type 2 diabetes, 
cardiovascular disease and osteoarthritis of the spine, knees and hips)  will demand an even larger portion  of  future 
public health expenditures.  
   
The purpose of this review is to acquaint radiologists with the current state of the art in the non-cardiac gated, non-
contrast chest computed tomography (NG-NCCT) cardiovascular imaging biomarkers found patients with obesity and 
the metabolic syndrome (MetS) and their prognostic significance. Our aim is to help identify those persons at risk 
using the metrics from these imaging biomarkers and to then recommend lifestyle interventions (weight reduction, 
increased physical activity and nutritional intervention) and a modification of medical management or surgery to 
improve patient outcomes.(10) 
 
Heart and great vessels  
 The progression of cardiac and vascular disease takes place over decades and is for the most part 
asymptomatic. Thus, without testing the patient is not aware of the degree of his/her atherosclerotic burden. NG-
NCCT can detect and quantify early heart disease and serve as a prognostic marker, particularly in patients with 
MetS. Madaj and Budoff published a nice summary of the risk stratification that NCCT can provide.(11) Given the 
limited soft-tissue contrast of non-enhanced CT, most prognostic markers are based on the quantification of 
calcification - either as part of vascular arteriosclerosis or valve leaflet calcification. While all cardiac structures are 
affected by cardiac motion, there is increasing evidence that, with newer hardware, and faster gantry rotation times, 
low-dose NG-NCCT cardiac motion is less of a problem for calcification and myocardial scar 
assessment/quantification (Figures 1-4).(12-15) Furthermore, arteriosclerosis is a systemic disease and although the 
association is stronger between atherosclerotic alteration and development of further events in the same organ 
segment (16), assessment of one vascular bed may serve as a proxy for an overall risk marker. However, a significant 
portion of potentially clinically significant cardiovascular findings are currently not mentioned in the written reports, 
particularly by junior radiologists.(17)  
Coronary artery Calcification 
 The most important non-acute finding on NCCT predictive of future major adverse cardiac events is 
coronary artery calcification (CAC) (Figures 2 and 4).  Broad evidence exists regarding the prognostic value of 
coronary artery calcification (CAC) for cardiovascular events (18-22). More importantly, the use of CAC improved 
risk stratification beyond existing, clinical risk scores. This was conclusively shown in the Heinz-Nixdorf RECALL 
included 4,487 subjects without known CAD.  With the addition of  CAC assessment to the Framingham-Risk-Score 
the area under the curve improved from 0.681 to 0.749 (p<0.003) and when CAC was added to the National 
Cholesterol Education Panel ATP III categories the area under the curve improved from 0.653 to 0.755 (18).  CAC 
was a much stronger predictor of risk than carotid intima-media thickness, high-sensitivity C reactive protein and 
the ankle-brachial index (19). Further results from the MESA study showed that CAC improves risk assessment in 
individuals with family history (19). Consequently, CAC assessment has been incorporated into many clinical 
guidelines for risk stratification. Depending on the guideline used, CAC is considered an appropriate test to 
perform in asymptomatic adults at intermediate risk for heart disease. These patients are defined by having a 10% 
to 20% 10-year risk or having a Systemic Coronary Risk evaluator (SCORE) (23) risk stratification value range of 5% - 
10%, low-risk individuals with a family history of premature disease and all diabetic patients 40 years or older are 
also candidates for this test. (24-26) Budoff and colleagues (22) have recently shown that in the MESA cohort 
(N=6814) (https://www.mesa-nhlbi.org/Calcium/input.aspx ) for each doubling of CAC there was a 14% increase in 
CVD risk. They concluded that CAC is highly associated with MACE and is this gated non contrast CT biomarker was 
found to be independent of standard risk factors (Supplementary Table S1).(22) 
................................................................................................................................................ 
 Evidence based guidelines for the use of CAC are based on publications using cardiac-gated CT. This is 
because CAC has a high density and is sensitive to motion artefacts leading to false CAC values (27). New 
technology of multi-detector computed tomography scanners with faster gantry rotation times and thinner 
detector row widths allow for thinner slices with a reduction in partial volume effects. These changes in hardware 
now allow for more exact and reliable measurement of CAC on non-gated NCCT scans (NG-NCCT). In a study by Wu 
et al (28) on 483 patients showed excellent correlation of Agatston CAC scores between a dedicated cardiac gated 
non-contrast CT for calcium scoring (16 slice multidetector, 3.0 mm slice thickness) and a low dose NG-NCCT ( 16 
slice multidector,  0.75mm slice thickness )performed for lung cancer screening (Figure 1). In their cohort of NG-
NCCT patients the average heart was 61 beats per minute. They did not assess the importance of potential heart 
rate dependent motion artifact that may limit the accurate quantification of calcium score using non gated CT 
protocols.(28) They found an intraclass correlation coefficient of 0.95 for the agreement between the scores on 
low-dose NG-NCCT versus the respective routine cardiac-gated CT for CAC in this one observer study. In a study by 
Kim et al., where 128 patients underwent both non-gated low dose lung cancer screening and ECG-gated CAC 
scanning, an accuracy of 90% was observed for CAC>0 on the gated CAC scan and the absolute CAC scores 
correlated well (r=0.89) (29). In a meta-analysis of 661 subjects (3 separate studies) performed in 2013, Xie et al 
convincingly showed that, when the Agatston Score at non-gated low dose NCCT was compared with the gold 
standard of routine cardiac gated CT performed for CAC scoring, the pooled correlation coefficient was 0.94 
(95%CI: 0.89-0.96).  These data are confirmative of the newly available scatter plot from Wu et al(28) (Figure 1) 
showing a R2 of 0.95 between Agatston scores as derived from NG-NCCT versus cardiac gated CT. 
 While the Agatston score as a continuous measurement has been established for formal CAC assessment, 
the development of visual scores for CAC categorization is essential in order to provide the chest radiologist with a 
simple technique that is less time consuming. Several studies have been performed showing that either a visual-
qualitative assessment or a visual ordinal scale can be used for reliable and accurate risk assessment as compared 
to Agatston score (30-32). But more importantly, both Agatston score and/or a visual CAC assessment from NG-
NCCT have prognostic value for cardiovascular events and overall mortality. In detail, a study performed by Mets et 
al in 3,648 lung cancer screening patients using an automatically derived Agatston score from NG-NCCT in a risk 
prediction model found overall good discrimination (AUC 0.71) with an event frequency of 12.2% vs 4.0% in the high 
vs. low risk groups, respectively.(33)          In the ECLIPSE trial Williams et al found that CAC was increased in patients 
with chronic obstructive pulmonary disease and was associated with an increased risk of death.(34) In the National 
Lung Screening Trial assessing 1,442 patients (35), an Agatston scores of 1-100, 101-1000, and >1000 had HR of 1.27, 
3.57, and 6.63 as derived from NG-NCCT and compared to an Agatston score of 0. Interestingly, in a case-control 
study authored by Hughes-Austin et al. in which both  ECG-gated 3 mm and non-gated 6 mm CT scans were available, 
the predictive value of the Agatston score for mortality where similar.(36) Focusing on visual assessment, Shao et al 
showed in a single centre study that there is no significant difference in the discriminative power of visual CAC 
assessment vs. Agatston score (AUC: 0.80, 0.81).(37) Most evidence exist for a visual assessment using an ordinal 
CAC scoring system categorizing from 0-12 or 0-30 based upon visual estimation (Table 1). The study of Shemesh et 
al. including 8,782 smokers with 72 months mean follow up showed that this simple ordinal system was strongly 
predictive for cardiovascular death (32) and further confirmed by Blair et al. to be  of similar predictive value  as the 
Agatston score (31) (Table 2).  Gonzales et al have recently shown that automated detection of Agatston scores can 
be derived from NG-NCCT exams.(38) Thus, in a common guideline, the Society of Cardiovascular Computed 
Tomography (SCCT) and the Society of Thoracic Radiology (STR) recommend “the incorporation of CAC into all non-
gated non-contrast chest examination reports” since it “in the treatment of coronary artery disease“.(39) 
 It is very clear that coronary artery calcium can be reliably detected on NG-NCCT and that either ordinal 
scoring methods or quantification of the NG-NCCT Agatston score are highly correlated (within 10%) with those 
cardiac gated non-contrast CT exams that are performed only for CAC scoring.  An argument can be made that the 
CAC score value obtained using current state of the art multidetector NG- NCCT of the chest, performed for any 
reason, are a good proxy for a dedicated CAC scoring CT. 
    
Aortic calcification 
 The thoracic aorta is another important vascular bed imaged on a standard chest CT. As compared to the 
coronary arteries, the assessment thoracic aorta calcification (TAC) less standardized but also less effected by cardiac 
motion. In a retrospective study by Jairam et al. found good predictive value for cardiovascular events when including 
visual assessment of TAC (HR: 0.37, p<0.001) into a larger predicting model.(40) Similar results were observed in the 
Heinz Nixdorf RECALL study (41), where TAC together with other CT-derived parameters improved the prediction of 
events over the Framingham Risk Score and CAC (AUC: 0.749 to 0.764; p=0.01). In contrast, Kim et al found in subjects 
from the MESA study without CAC (n=3,415) that TAC was associated to cardiovascular events and all-cause 
mortality, but this association attenuated after adjustment for cardiovascular risk factors.(42) Similarly, in the 
Framingham Heart Study TAC provided no incremental value above risk factors for the prediction of events.(43) 
Thus, TAC is a prognostic marker, but its incremental value to traditional risk factors and other CT-findings, particular 
to CAC remain controversial.  
Valvular Calcification  
 The most common valve affected by calcification is the aortic valve. The aortic valve calcification (AVC) can 
vary by its degree and/or by its location and can lead to aortic stenosis. The degree of stenosis is increasing with AVC 
extent, while calcification of the peripheral left-posterior and the central right-left commissural leaflets is particularly 
correlated with mean and peak gradient increases across the aortic valve.(44) The underlying pathophysiology is 
complex and integrates lipids, the renin-angiotensin system, inflammation, signalling pathways, and genetic 
predisposition.(45) Also, a strong linkage to visceral obesity has been described leading the neologism ‘valvulo-
metabolic’ risk.(46) Further, AVC shares common risk factors with arteriosclerosis; hence, patients with AVC had 
more frequently coexisting presence of coronary plaque and had a greater extent of coronary plaque burden (6.4 vs 
1.8 segments for patients with and without AVC, P<0.001) as described in a study of 357 subjects undergoing cardiac 
CT. (47) Interestingly, AVC was more strongly associated with calcified (OR: 5.2, p=0.004), then with mixed (OR: 3.2, 
p=0.02) or non-calcified plaque (P=0.96). Several studies have been performed regarding the prognostic value of 
AVC for cardiovascular events and all-cause mortality. Although AVC showed a prognostic value in univariate 
analysis, it attenuated in most studies after adjustment for traditional risk factors and after further adjustment for 
CAC and/or TAC.(43, 48-50) 
Annular Calcification 
 The annulus of the mitral valve is most commonly calcified. Mitral annular calcification (MAC) is a chronic 
degenerative process in the fibrous base of the mitral valve and more commonly affects the posterior annulus than 
the anterior annulus. (51) Traditionally, MAC is assessed using echocardiography and several studies using this 
technology showed independent association of MAC with cardiac events.(52, 53) Given a good relationship in MAC 
between echocardiography and CT (54), MAC was also a good predictor for cardiovascular events if assessed by CT 
(55, 56). In the Northern Manhattan Study (n=1,955) (55), MAC prevalence was 27%, while severe MAC (>4mm 
thickness) was observed in 13%. Presence of MAC was associated with myocardial infarction (HR: 1.75) and cardiac 
death (HR: 1.53) and these associations became stronger if using severe MAC as the predictor (HR: 1.89 and 1.81; 
respectively). In this cohort, but also in a cohort with atrial fibrillation, MAC was not significantly associated with 
cerebrovascular events. (55, 56)    
 Caseous calcification of the mitral valve is a rare form of MAC. The contents of the hollowed out cavity in 
the mitral valve annulus is composed of a mixture of calcium, fatty acids, and cholesterol that has a ‘‘toothpaste-
like’’ texture. This commonly presents as an intracardiac mass at echocardiography. There is limited evidence 
regarding the prognostic value of caseous calcification of the mitral annulus. In a literature review of 1,502 articles, 
Dietl et al. identified a total of 130 patients with caseous calcification of the mitral annulus reported in 86 
publications. The prevalence of cerebrovascular events was higher in patients with caseous calcification of the mitral 
annulus than with simple MAC (19% vs 12%, respectively; p=0.02).  
Atrial and Ventricular size 
 There is a large body of evidence that MetS carries an increased risk of left ventricle (LV) hypertrophy, left 
atrial (LA) enlargement, systolic and/or diastolic dysfunction, arrhythmias and interstitial myocardial fibrosis.  MetS 
is also associated with increased LV mass and LV diastolic dysfunction.(57, 58)  CT can be useful for assessing cardiac 
chambers to determine their size, shape and thickness. Cardiac gated CT scans can usually be obtained during 
diastole for CAC scoring and coronary angiography, as this phase of the cardiac cycle has the least motion. While 
chamber assessment is relatively simple for gated, contrast-enhanced CT scans given existing software tools, NG-
NCCT exams are more challenging and an area-based approach has been proposed. Schlett et al. showed that an 
area-based measurement for LV on axial, non-contrast enhanced CT images correlates well with LV volume, mass 
and size (r=0.68; r=0.73; r=0.82).(59) Similar correlations were observed for the left atrium.(60) In the MESA cohort, 
such area-based LV measurement of non-contrast CT scans is a predictor of incident heart failure events (HR 1.15; 
95%CI 1.11-1.20) beyond traditional risk factors and CAC score; but also for CHD events (HR 1.07; 95%CI 1.03-1.10). 
As RV and LV contraction is usually synchronous, the RV/LV diameter and volume ratios have been used in NG-NCCT 
studies to assess RV dilation and dysfunction in response to increased RV afterload. (Henzler et al 2012, Mansencal 
et al. 2005) A limited number of reports indicate that RV hypertrophy may parallel alterations in LV structure and 
function in the setting of systemic hypertension, obesity and diabetes. (Chahal et al 2012) All the components of 
MetS (increased blood pressure, abdominal obesity, increased fasting glucose level and dyslipidemia) may induce 
right ventricular remodelling by several hemodynamic and non-hemodynamic mechanisms. (Tadic et al. 2013)  
Increasing evidence suggests that in pulmonary hypertension (PH) RV dysfunction is associated with various 
components of MetS, such as insulin resistance, hyperglycemia, and dyslipidemia. (Talati et al. 2015)  
 Regarding LA assessment, an enlarged size was associated with a 3- to 5-fold increase risk for ACS and 
provided incremental value for predicting ACS when added to the CT finding of indeterminate coronary artery 
stenosis in a population with acute chest pain presenting to the ED. (61)  In the Heinz-Nixdorf Recall Study (62), LA 
size had prognostic value (HR 1.48), which remained significant after adjustment for traditional risk factors (HR 
95%CI: 1.09-1.43) and after adjustment for  traditional risk factors plus CAC (HR 95%CI: 1.07-1.40) (Table 2). 
Prognostic value of LA size was similar for different endpoints (coronary event: HR: 1.21; stroke: 1.31; CV death: 
1.33). LA size also remained associated with cardiovascular events independent of other CT non-coronary 
findings.(41) Recently Jivraj et al have shown in 165 patients with right heart catheterization proven pulmonary 
hypertension (PAP > 45 mm Hg) and capillary wedge pressures (43 patients - PCWP > 15 mm Hg, 122 patients 
PCWP < 15 mm Hg) that left atrial maximal cross-sectional area (LA-MACSA) measured from NG-NCCT (LA-MACSA > 
2400mm2, P<0.001) had a 44% sensitivity and 93% specificity for pulmonary hypertension from left heart disease.(63) On NG-
NCCT studies the images may not reveal the true ventricular morphology because the phase of the cardiac cycle is 
unknown. However, a few studies have reported good sensitivity and specificity (both >68%) of standard axial, 
non-gated chest CT for cardiomyopathies. (64)  
Left ventricle 
 The left ventricle size (volume and in-plane area) can be estimated from NCCT chest exams. Bhatt and 
colleagues (65) have created an automated process for generating the expected ventricular sizes from NG-NCCT 
chest exams by comparing these studies to ultrasound and cardiovascular MRI exams that show the ventricular 
volumes and wall thickness (Supplemental Figure 1). The assessment of ventricular volume and wall thickness is 
easier if the patient is anemic, as the ventricular chambers are seen to be of lower Hounsfield unit density than the 
walls. The presence of prior left ventricular myocardial infarction is also easily determined by the presence of a low 
density scar (Figure 3). These are typically seen in the subendocardial regions of the wall and may be transmural.  
 Recently Kockelkoren et al published their data from routine NG-NCCT exams on patients that were studied 
for non-cardiovascular disease (Tables 3 and 4). This was derived from a rather homogeneous population of 
Caucasians in the United Kingdom. This group of researchers created a simple to use ordinal grading scale for the 
determination of future major adverse cardiac events (MACE) (Table 3) and have a computational model for the 
likelihood of a major cardiac event within 5 years that is based on a best fit multivariable regression model 
(Supplementary Tables S2, S3). The parameters include: age, male gender, indication for exam, left anterior 
descending coronary artery calcium (LAD Ca++) value, mitral valve leaflet calcification (MV CA++) value, descending 
aorta calcium value (DSC Ca++), and the maximum transverse diameter (cm) of the heart. 
Epicardial Fat 
 In their study of 3,630 subjects from the Heinz-Nixdorf  Recall Study, Mahabadi et al(41) found that the 
epicardial fat volume (HR: 1.15, 95% C.I 1.01-1.30, p value 0.03),  was an imaging biomarker predictive of myocardial 
infarction, stroke and cardiovascular death (Table 5). In their systematic review, Bertaso et al found that the 
heterogeneity of the studies limits the conclusions that can be drawn from using this metric. They found that this 
visceral fat deposit is highly correlated with obesity, diabetes mellitus, age and hypertension. Manno et al showed 
that epicardial fat thickness at ultrasound was correlated with higher LDL cholesterol.(66) In their study from 2018, 
Hedgire et al show that perivascular fat stranding, seen on coronary CT angiography is associated with high risk 
clinical features and they suggest that fat stranding is a potential imaging biomarker of high-risk and/or ruptured 
atherosclerotic plaques.(67) Hartiala et al found no evidence that increased epicardial fat volume was independently 
associated with pre-clinical atherosclerosis.(68) Instead, they found that epicardial fat volume was primarily 
associated with BMI and waist circumference.(68) Furthermore, there is increasing evidence that fat quality rather 
fat volume may play a role in the association to CVD. (69) 
Pulmonary artery diameter predicts pulmonary hypertension 
 Sleep disordered breathing (sleep apnea) is an important cause of pulmonary hypertension.(70)  
Obstructive Sleep Apnea (OSA) is caused by the increased collapsibility of the upper airway from loss of muscle tone 
and a decrease in the effective orifice from fat deposition in the tongue and surrounding pharynx during sleep.(71) 
This results in decreased or absent airflow and hypoxia. These episodes are usually terminated by a brief arousal 
from sleep and resulting in sleep deprivation for subjects with MetS.(72)  Over many years, these apneic episodes 
lead to sleep fragmentation and altered cognitive function. (73) These episodes of hypoxia are associated with 
pulmonary artery vasoconstriction and can lead to permanent changes in PA size (Figure 5).(74) Corson et al studied 
175 subjects with right heart catheterization (RHC)  proven pulmonary hypertension (PH), 16  normal patients with 
proven normal  mean pulmonary artery pressures (mPAP) and 114 subjects without known mPAP and found a 
sensitivity of the criterion “mean pulmonary artery diameter at the level of the bifurcation >29mm” was 0.89 (95% 
C.I. 0.84-0.93) and a specificity of 0.83 (95%CI: 0.76-0.90).(75) Truong et al  studied 706 “healthy cohort” subjects in 
the Framingham Heart Study using cardiac gated NCCT and found a 90th percentile cut-off value of 28.9 mm in men 
and 26.9 mm in women.(76) Pulmonary artery diameter is an important clue that may indicate pulmonary 
hypertension from any cause (77);  in the setting of obesity or MetS an enlarged PA can  be used to alert the imager 
and clinician to the possibility for OSA.  Instituting treatment with Continuous Positive Airway Pressure (CPAP) can 
significantly improve the length and quality of life for these individuals. 
Radiation dose and safety using NG-NCCT for the diagnosis of MetS 
 We are not proposing to use NCCT for the diagnosis of MetS or obesity. From studies performed for other 
indications, the imaging physician can also make inferences about the metabolic milieu of that subject based on the 
multiple imaging findings discussed in this review. For the most, part low dose chest CT protocols are very low 
contributors to the medical radiation any patient receives over the course of their lifetime.(78)  Each scan delivers 
between 0.5 and 5 mSv depending on the patient size, use of dose lowering reconstruction methods and automatic 
exposure control (limit mAs).(79) 
Conclusion  
 The beauty of non-gated, non-contrast computed of the chest is that quantitative assessment of Hounsfield 
unit density, contour and volume of many organs can be assessed longitudinally and correlated to patient outcomes. 
This differs substantially from contrast enhanced CT data, because there is no iodinated contrast material 
confounding the density measurements. There are easy to access imaging biomarkers associated with obesity, 
atherosclerotic disease and MetS that are routinely seen on these exams. The most important one found on NG-
NCCT is coronary artery calcification. Various models combining clinical and imaging data have been shown to have 
prognostic significance for Major Adverse Cardiac Events. Thus, these exams are a virtual treasure trove of 
quantitative imaging biomarker information available for retrospective analysis to create survival models (training 
sets) that can be applied prospectively to test sets and validated with external data sets. These big data can be added 
to radiomic feature analysis, convolutional neural networks and/or added to deep neural networks without any user 
defined features to create better survival models that can be used to help design personalized medical interventions 
aimed at prolonging quality life expectancy. 
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Legend Figure 1:  Data from Wu et al (28) in a study comparing Agatston Calcium Scores on non-cardiac gated, 
non-contrast low dose CT (LDCT) performed for lung cancer screening to standard cardiac gated, non-contrast 
computed tomography (NCCT) in 513 consecutive cases. This shows excellent correlation between these two ways 
to quantify Agatston coronary artery calcification scores (R2=0.95). They found a systematic under quantification 
of CAC using LDCT (y intercept = -12.1). Thus, any coronary artery calcification found at LDCT is worthy of 
quantification. This can be performed either by ordinal scoring or using post processing to obtain the non-cardiac 
gated LDCT Agatston score. (Scatter plot of the raw data made expressly for this article by Ming-Ting Wu, M.D.) 
Legend Figure 2:  Non gated, non-contrast computed tomography of the chest with globular calcification of an 
atherosclerotic plaque at the origin of the left anterior descending coronary artery (arrow head). 
Legend Figure 3: Non-gated, non-contrast computed tomography of the chest coned down to the heart (A) axial 
and (B) short axis reconstruction showing a fibrofatty subendocardial scar (arrows) in the left ventricular septum, 
inferior and inferolateral walls from an old myocardial infarction in the right coronary artery vascular territory.  
Note the presence of hepatic steatosis as well (A) with a liver density of 35 Hounsfield units (ROI -Region of 
interest). 
Legend Figure 4:  45 year old Caucasian male with(A) borderline evidence  for low iodine organification in the 
thyroid with a thyroid density of 64 ( Normal range 80-120 HU) (B)  non gated Agatston score of 2 is at least in the 
79th percentile for age and sex. There was hepatic steatosis as well (C) with a liver density of 42.9 HU. The 
paraspinous muscle density was low measuring 33.8 HU at the T12 level (Normal range 5-60HU, from unpublished 
data (Tsuchiya et al, submitted)). This constellation of findings is the imaging equivalent of the clinically defined 
Metabolic Syndrome and suggests both glucose intolerance and an increase in overall inflammatory cytokines due 
to the low paraspinous muscle density. 
Legend Figure 5: Pulmonary trunk measured at the largest part of the right main pulmonary artery is 4.0 cm (white 
line). This is abnormal and is suggestive of the possibility of pulmonary hypertension/pulmonary arterial 
hypertension. In an obese individual a common cause is sleep disordered breathing (sleep apnea) which can be 
treated with a night time Continuous Positive Airway Pressure (CPAP) mask. 
Legend Supplemental Figure 1: Automatic segmentation of the left and right ventricular cavities from non contrast 
non cardiac gated chest CT exams using the method of Bhatt et al (65), (A) axial chest CT with the estimated left 
ventricle cavity in light red  and the estimated left ventricular wall in dark red, with the estimated right ventricle in 
blue, (B) sagittal non contrast CT showing the  estimated left  ventricle in red and the estimated right ventricle in 
blue. (C) coronal chest CT showing the estimated left ventricle in red and the estimated right ventricle in blue, (D) 
Entire volume of left ventricle in red and right ventricle in blue. 
Legend Table 1: Importance  of coronary artery calcification found on non-cardiac gated chest computed 
tomography in patients that smoke cigarettes (table modified from Shemesh et al) (80) Practical comments for 
chest radiologists showing that the larger ordinal coronary artery calcium score is associated with an increased risk 
of Major Adverse Cardiac Events. (This table is modified from Shemesh et al (80)) Abbreviations: CAC- coronary 
artery calcium score; Visual Score (Likert Scale range from 0-12); CAD- coronary artery disease, PVD- peripheral 
vascular disease; 
Legend Table 2: Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are 
reflective of individual biology and the metabolic syndrome. (Abbreviations: n- number affected. N=total in study) 
Legend Table 3: Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N= 
2124) (81). This type of analytic approach to documenting vascular calcifications was first used by Jairam et al in 
2014 (40). 
Legend Table 4: Hazard Ratios for the most significant model parameters for determining cardiovascular risk from 
contrast enhanced, non-gated chest CT exams from the PROVIDI study (N=10,410)   (40). 
 
Legend Table 5: Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 
3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorff Recall Study. (41) and their adjusted Hazard 
Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk 
Score, CAC- Coronary artery Agatston Score,)  
 
Legend Table S1: Multi-Ethnic Study of Atherosclerosis  (MESA) results from Budoff et al(22)  modified from Table 
2 in the original publication, showing the ten year event rate of major adverse cardiac events based simply off of 
the gated CT chest coronary artery Agatston calcium scores. These event rates are not adjusted for any clinical risk 
factors. These data show the effects of CAC transcend age related changes; in that more CAC is worse than simply 
being old. The   Chinese and Caucasian were less affected by CAC than African-Americans and Hispanics. 
Legend Tables S2 and S3: Kockelkoren (81) Scottish heart study risk 10 year estimated risk model (Table S2) and 
the equation used to derive the 5 year risk score (Table S3) 
 
Figure 1 Click here to access/download;Figure;Figure 1 MetS.tif
Figure 2 Click here to access/download;Figure;Mets figure 2  LAD Ca++ 600 dpi.tif
Figure 3 Click here to access/download;Figure;Mets Figure 3 RCA infarct scar on NCCT axial
and short axis.tif
Figure 4 Click here to access/download;Figure;Mets Figure 4 a b c  dpi.tif
Figure 5 Click here to access/download;Figure;Mets Figure 5 PartI  4.0cm PA.tif
Supplemental figure 1 Click here to access/download;Figure;JTI Schlett Supplemental figure 1 600 dpi.tif










Prognosis  Recommendation Comment 






The presence of chronic 
obstructive CAD is very 
unlikely, life style changes 
Might be false 
negative  





the visual score is 
less sensitive  
in subjects with 
low CAC burden 
Mild CAC 1-100 1-4 Mildly 
increased 
risk for CV 
event 
Consider further coronary 
evaluation and primary 
preventive treatment 
according to the patient 
global risk, life style changes 





101-400 5-7 Mildly 
increased 
risk of CV 
event 
Consider further coronary 
evaluation and primary 
preventive treatment 
according to the patient 
global risk and clinical 
manifestations; in patients 
with Framingham risk 
intermediate and above 
(≥10% in 10 years) statin 











In asymptomatic subjects, 
consider further coronary 
evaluation by stress ECG, 
stress echo or SPECT imaging 
to R/O obstructive CAD; statin 
therapy should be highly 
considered. 
Mostly prevalent 
in old patients  
and in those with 
clinical CAD, PVD 
and renal failure 
Table 1: Importance  of coronary artery calcification found on non-cardiac gated chest computed tomography in 
patients that smoke cigarettes (table modified from Shemesh et al) (70) Practical comments for chest radiologists 
showing that the larger ordinal coronary artery calcium score is associated with an increased risk of Major Adverse 
Cardiac Events. (This table is modified from Shemesh et al (70)) Abbreviations: CAC- coronary artery calcium score; 






Non contrast,  
Chest CT finding 























diameter of heart 
    Leiner article 




















2,146 ± 275 
[3389/3630] 



















































































at Pul Art 
bifurcation 
35.5 ± 4.0 
[3389/3630] 























































Legend Table 2: Imaging findings on non-contrast, non-cardiac gated Chest Computed tomography exams that are 

















artery calcification  
 none 1 or 2 calcified 
plaques limited to 
2 or fewer images 
Greater than 2 focal 
plaques or calcification 
extending for more 
than 2 slices 
Fully calcified  
coronary artery 
extending for more 
than 3 slices 
Descending Thoracic 
Aorta Calcification 
none Less than or equal 
to 3 focal calcified 
plaques 
4-5 focal calcified 
plaques or one plaque 
extending for 3 or more 
slices 
More than 5 focal 
calcified plaques or 2 
plaques extending 
beyond 3 slices 
Mitral valve leaflet 
Calcification 






Legend Table 3: Imaging based cardiovascular risk biomarkers derived from a Caucasian population in Scotland (N= 







Model feature Hazard Ratio P value 
Male 1.41 <0.001 
Descending Aorta Calcification 1.45 <0.001 
Mitral Valve Calcification 1.25 <0.001 
LAD Calcification 1.11 <0.003 
(Maximum Transverse Cardiovascular diameter in cm  -
11cm)2 
1.03 <0.001 
Age 1.03 <0.001 
Legend Table 4: Hazard Ratios for the most significant model parameters for determining cardiovascular risk from 
contrast enhanced, non-gated chest CT exams from the PROVIDI study (N=10,410)   (36). 
 
Table 4
Table 5  
 
Model feature Hazard Ratio 
Adjusted for FR score, CAC 




Left atrial index 1.21 
(1.07-1.36) 
0.002 
Left ventricular index 1.15 
(1.02-1.29) 
0.02 
Epicardial Fat Volume 1.14 
(1.01-1.28) 
0.04 
Presence of Thoracic Aortic Calcification 1.14 
(0.83-1.56) 
0.43 
Diameter of Ascending aorta 0.98 
(0.84-1.15) 
0.25 
Aortic Valve Calcification 1.01 
(0.72-1.40) 
0.98 
Diameter of the Descending thoracic Aorta 0.98 
(0.84-1.15) 
0.84 





Legend Table 5: Multivariable analysis of clinical and imaging based cardiovascular risk biomarkers derived from 
3,630 subjects enrolled in the prospectively acquired Hienz-Nixdorff Recall Study. (37) and their adjusted Hazard 
Ratios for the interval development of major adverse cardiac events (MACE). (Abbreviations: FR- Framingham Risk 
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